肾素-血管紧张素系统阻断剂治疗代谢综合征的进展  

Advances in Renin-Angiotensin System Blockades in Treating Metabolic Syndrome

作　　者：张凤[1] 周华梅[1] 张霞[1] 

机构地区：[1]重庆医科大学附属第二医院消化内科,重庆400010

出　　处：《中国药业》2012年第6期17-19,共3页China Pharmaceuticals

摘　　要：代谢综合征以胰岛素抵抗为主要特征,是心血管疾病的危险因素。非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)是代谢综合征在肝脏的表现。肾素-血管紧张素系统(renin-angiotensin system,RAS)的激活参与了代谢综合征的发生、发展,阻断RAS的激活是代谢综合征的治疗途径之一。RAS阻断剂包括血管紧张素转换酶抑制剂(angiotensin converting enzyme inhibitor,ACEI)和血管紧张素Ⅱ受体拮抗剂(angiotensin receptor blockade,ARB),可降低血压、改善胰岛β细胞功能和胰岛素抵抗,但RAS阻断剂对NAFLD的疗效尚存在争议。该文就RAS阻断剂治疗代谢综合征的进展进行了综述。Insulin resistance is a key characteristic of metabolic syndrome, which is considered as a predictor of cardiovascular diseases. Nonalcoholic fatty liver disease （NAFLD） is a hepatic manifestation of metabolic syndrome. The activation of renin-angiotensin system （RAS） is involved in the development of metabolic syndrome. The inhibition of RAS activation is an effective treatment of metabolic syndrome. RAS blockades, including angiotensin converting enzyme inhibitor （ACEI） and angiotensin receptor blockade （ARB）, can decrease blood pressure, improve islet betacell function and insulin resistance. However, there is still a controversy about the effect of RAS blockades on NAFLD. In this article, current evidence concerning RAS blockades in the treatment of metabolic syndrome will be reviewed.

关 键 词：代谢综合征 肾素-血管紧张素系统 非酒精性脂肪性肝病 进展 

分 类 号：R587[医药卫生—内分泌] R589[医药卫生—内科学]